Literature DB >> 30829694

The Pattern of Residual Tumor After Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer and Its Clinical Significance.

Tadayoshi Hashimoto1, Tomoki Makino1, Makoto Yamasaki1, Koji Tanaka1, Yasuhiro Miyazaki1, Tsuyoshi Takahashi1, Yukinori Kurokawa1, Masaaki Motoori2, Yutaka Kimura3, Kiyokazu Nakajima1, Eiichi Morii4, Masaki Mori1, Yuichiro Doki1.   

Abstract

OBJECTIVES: To investigate the residual pattern of esophageal cancer in the esophageal wall after neoadjuvant chemotherapy (NAC) and its clinical significance.
BACKGROUND: NAC is a standard treatment for locally advanced esophageal cancer; however, residual tumor patterns in resected specimens after NAC and their clinico-pathological characteristics remain unknown.
METHODS: One hundred twenty consecutive patients with cT3 or deeper esophageal cancer underwent curative esophagectomy after NAC and achieved grade 2 histological responses between 2000 and 2016. Hematoxylin-eosin staining of residual tumor sections revealed 4 remnant categories: Type 1: shallow, Type 2: central, Type 3: deep, and Type 4: diffuse. We examined associations between these Types and clinico-pathological factors, including prognosis.
RESULTS: Forty-five (38%) specimens had no residual tumor cells in the mucosal layer. The adventitia layer displayed the lowest residual tumor cell frequency (18%) among all layers. Types 1, 2, 3, and 4 residual tumor patterns were found in 49 (41%), 33 (28%), 9 (8%), and 29 (24%) patients, respectively. Type 4 showed the maximum standard uptake value after NAC; Types 3 and 4 had higher ratios of venous invasion than Type 1 or 2. Patients with Type 3 or 4 more frequently developed pleural dissemination or distant metastasis than patients with Type 1 or 2. Survival was similar among the 4 Types.
CONCLUSIONS: After NAC for locally advanced esophageal cancer, the shallow residual tumor pattern was most common, but approximately 40% of specimens showed no tumor cells in the mucosal layer. Deep and diffuse remnant patterns were associated with high risks of pleural dissemination and distant metastasis.

Entities:  

Mesh:

Year:  2020        PMID: 30829694     DOI: 10.1097/SLA.0000000000003129

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  Why is endosonography insufficient for residual diagnosis after neoadjuvant therapy for esophageal cancer? Solutions using muscle layer evaluation.

Authors:  Shohei Yonemoto; Masaya Uesato; Akira Nakano; Kentaro Murakami; Takeshi Toyozumi; Tetsuro Maruyama; Hiroshi Suito; Tomohide Tamachi; Manami Kato; Shunsuke Kainuma; Keisuke Matsusaka; Hisahiro Matsubara
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

2.  ASO Author Reflections: Peritumoral Lymphatic Vessels as a Predictor of Response to Chemotherapy and Survival in Esophageal Cancer.

Authors:  Tomoki Makino; Takeo Hara; Yuichiro Doki
Journal:  Ann Surg Oncol       Date:  2020-04-20       Impact factor: 5.344

3.  Peritumoral Lymphatic Vessels Associated with Resistance to Neoadjuvant Chemotherapy and Unfavorable Survival in Esophageal Cancer.

Authors:  Takeo Hara; Tomoki Makino; Makoto Yamasaki; Koji Tanaka; Kotaro Yamashita; Yuya Nogi; Takuro Saito; Tsuyoshi Takahashi; Yukinori Kurokawa; Mitsuaki Tatsumi; Kiyokazu Nakajima; Eiichi Morii; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Ann Surg Oncol       Date:  2020-04-23       Impact factor: 5.344

4.  Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.

Authors:  Wenwu He; Tianqin Mao; Jiaxin Yan; Xuefeng Leng; Xuyang Deng; Qin Xie; Lin Peng; Qiong Liao; Marco Scarpa; Yongtao Han
Journal:  Ann Transl Med       Date:  2021-04

5.  Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003).

Authors:  Keijiro Sugimura; Makoto Yamasaki; Takushi Yasuda; Masahiko Yano; Motohiro Hirao; Kazumasa Fujitani; Yutaka Kimura; Hiroshi Miyata; Masaaki Motoori; Atsushi Takeno; Osamu Shiraishi; Tomoki Makino; Takayuki Kii; Koji Tanaka; Taro Satoh; Masaki Mori; Yuichiro Doki
Journal:  Ann Gastroenterol Surg       Date:  2020-11-28

6.  Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).

Authors:  Shujie Huang; Hansheng Wu; Chao Cheng; Ming Zhou; Enwu Xu; Wanli Lin; Guangsuo Wang; Jiming Tang; Xiaosong Ben; Dongkun Zhang; Liang Xie; Haiyu Zhou; Gang Chen; Weitao Zhuang; Yong Tang; Fangping Xu; Zesen Du; Zefeng Xie; Feixiang Wang; Zhe He; Hai Zhang; Xuefeng Sun; Zijun Li; Taotao Sun; Jianhua Liu; Shuhan Yang; Songxi Xie; Junhui Fu; Guibin Qiao
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.